secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-08-06T11:01:44+00:00
Accession:  0001628280-26-053817
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q2 2026 net loss narrows to $7.2M; cash runway into H1 2028
--------------------------------------------------------------------------------

- Net loss of $7.2M vs $17.9M in Q2 2025; collaboration revenue $16.1M (up from $7.6M) due to catch-up adjustment.
- Cash, equivalents, and marketable securities $167.6M; runway into first half of 2028.
- FHD-909 Phase 1 trial in SMARCA4-mutant NSCLC advancing; combination with anti-PD-1 shows complete tumor regression in preclinical models.
- Selective EP300 degrader program targeting IND in 2027 for multiple myeloma and DLBCL; preclinical data outperforms clinical benchmark.
- CBPd-171 timeline delayed due to operational issue at third-party CRO; updated guidance pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/0001628280-26-053817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/fhtx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer